Evaluation of FebriDx® for the management of children with acute febrile respiratory infection

Enfermedades infecciosas y microbiologia clinica (English ed.) Pub Date : 2024-06-01 DOI:10.1016/j.eimce.2024.04.002

Paula de la Matta Farrando , Maria Teresa Suay Torres , Anna Sabater Sabate , Victoria Trenchs Sainz de la Maza , Carles Luaces Cubells , Susanna Hernández Bou

{"title":"Evaluation of FebriDx® for the management of children with acute febrile respiratory infection","authors":"Paula de la Matta Farrando , Maria Teresa Suay Torres , Anna Sabater Sabate , Victoria Trenchs Sainz de la Maza , Carles Luaces Cubells , Susanna Hernández Bou","doi":"10.1016/j.eimce.2024.04.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Acute respiratory infections (ARI) are a common cause of inappropriate antibiotic prescription (ATB) in pediatrics. FebriDx® is a rapid diagnostic test that differentiates between viral and bacterial infections. The objective is to analyse the impact of FebriDx® on ATB prescription when managing febrile ARI.</p></div><div><h3>Methods</h3><p>Prospective study carried out in patients aged 1–<18 years with febrile ARI in the emergency department. FebriDx® was performed and the impact on management was evaluated at follow-up.</p></div><div><h3>Results</h3><p>A total of 216 patients were included. Clinical assessment and FebriDx® result coincided coincided in 174 (80.5%) cases. A modification of the initial therapeutic plan was made in 22 (52.4%) of the 42 discordant ones (10.2% of the overall patients). In pneumonia the impact was 34.5%; in all cases it involved not prescribing ATB.</p></div><div><h3>Conclusions</h3><p>FebriDx® could be a useful tool in the management of pediatric patients with febrile ARI to optimize ATB prescription.</p></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2529993X24001059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Acute respiratory infections (ARI) are a common cause of inappropriate antibiotic prescription (ATB) in pediatrics. FebriDx® is a rapid diagnostic test that differentiates between viral and bacterial infections. The objective is to analyse the impact of FebriDx® on ATB prescription when managing febrile ARI.

Methods

Prospective study carried out in patients aged 1–<18 years with febrile ARI in the emergency department. FebriDx® was performed and the impact on management was evaluated at follow-up.

Results

A total of 216 patients were included. Clinical assessment and FebriDx® result coincided coincided in 174 (80.5%) cases. A modification of the initial therapeutic plan was made in 22 (52.4%) of the 42 discordant ones (10.2% of the overall patients). In pneumonia the impact was 34.5%; in all cases it involved not prescribing ATB.

Conclusions

FebriDx® could be a useful tool in the management of pediatric patients with febrile ARI to optimize ATB prescription.

查看原文本刊更多论文

对 FebriDx® 用于急性发热性呼吸道感染患儿治疗的评估。

导言：急性呼吸道感染（ARI）是儿科不适当抗生素处方（ATB）的常见原因。FebriDx®是一种快速诊断测试，可区分病毒和细菌感染。目的是分析FebriDx®对处理发热性ARI时抗生素处方的影响：方法：对 1 岁以下患者进行前瞻性研究：结果：共纳入 216 名患者。174例（80.5%）患者的临床评估结果与FebriDx®结果一致。在 42 例不一致的病例中，有 22 例（52.4%）（占全部患者的 10.2%）修改了最初的治疗方案。对肺炎的影响为 34.5%；在所有病例中，均未开具 ATB：结论：FebriDx® 是治疗发热性急性呼吸道感染儿科患者的有效工具，可优化 ATB 处方。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Enfermedades infecciosas y microbiologia clinica (English ed.)

自引率

0.00%

发文量